Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 2/20 | 0.33 |
| ▸ | LATS1 | O95835 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.31 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16244938 | 0.89 | PTGDR2 (0.42) | PTGDR2BRD4LATS1L3MBTL1PCSK9 | |
| SCHEMBL2319229 | 0.84 | LATS1 (0.35) | PTGDR2BRD4LATS1L3MBTL1PCSK9 | |
| SCHEMBL2315168 | 0.83 | EED (0.32) | BRD4LMNAPCSK9ALDH1A1 | |
| SCHEMBL2314750 | 0.83 | PTGS1 (0.37) | PTGDR2BRD4LATS1L3MBTL1LMNA | |
| SCHEMBL2315327 | 0.82 | LMNA (0.43) | PTGDR2BRD4LMNAPCSK9KDM4E | |
| SCHEMBL1932988 | 0.82 | PCSK9 (0.35) | PTGDR2BRD4LMNAPCSK9ALDH1A1 | |
| SCHEMBL2320310 | 0.81 | LATS1 (0.37) | PTGDR2LATS1L3MBTL1LMNAKDM4E | |
| SCHEMBL2319582 | 0.81 | EED (0.39) | KDM4ESMN1; SMN2 | |
| SCHEMBL1933394 | 0.80 | PCSK9 (0.34) | PTGDR2BRD4LMNAPCSK9 | |
| SCHEMBL2319888 | 0.80 | PTPN11 (0.34) | PTGDR2LATS1L3MBTL1LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140349970-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2014-11-27 | — | — | US | disclosed |
| US-8785639-B2 | Substituted dihydropyrazolo[3,4-D]pyrrolo[2,3-B]pyridines and methods of use thereof | ABBVIE INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20110190489-A1 | Novel Tricyclic Compounds | ABBOTT LABORATORIES (US) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349970-A1 | NOVEL TRICYCLIC COMPOUNDS | CCNI, IL2, IL4I1 | PTGDR2 237/4885BRD4 1047/4885LATS1 3397/4885 |
| US-20110190489-A1 | Novel Tricyclic Compounds | CCNI, IL2, IL4I1 | PTGDR2 237/4885BRD4 1047/4885LATS1 3397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.